Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Invested Capital (2016 - 2026)

Heron Therapeutics filings provide 16 years of Invested Capital readings, the most recent being $9.1 million for Q1 2026.

  • On a quarterly basis, Invested Capital rose 132.11% to $9.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.1 million, a 132.11% increase, with the full-year FY2025 number at $14.3 million, up 142.59% from a year prior.
  • Invested Capital hit $9.1 million in Q1 2026 for Heron Therapeutics, down from $14.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $24.0 million in Q1 2022 to a low of -$40.0 million in Q3 2024.
  • Median Invested Capital over the past 5 years was -$27.3 million (2025), compared with a mean of -$13.9 million.
  • Biggest five-year swings in Invested Capital: plummeted 350.32% in 2023 and later soared 142.59% in 2025.
  • Heron Therapeutics' Invested Capital stood at $13.6 million in 2022, then crashed by 350.32% to -$34.0 million in 2023, then grew by 0.95% to -$33.7 million in 2024, then surged by 142.59% to $14.3 million in 2025, then plummeted by 36.25% to $9.1 million in 2026.
  • The last three reported values for Invested Capital were $9.1 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025) per Business Quant data.